Table of Content


1.    REPORT OVERVIEW    12

1.1    Statement of the Report    12
1.2    Executive Summary    14

1.3    INTRODUCTION    15

1.3.1     Cord Blood: An Alternative Source for HPSCs    15
1.3.2     Utilization of Cord Blood Cells in Clinical Trials    15
1.3.3     The Struggle of Cord Blood Banks    16
1.3.4     Emerging Technologies to Influence Financial Sustainability of Banks    16
1.3.4.1     Other Opportunities to Improve Financial Stability    16
1.3.4.2     Scope for Companion Products    17
1.3.5     Changing Landscape of Cord Blood Cell Banking Market    17
1.3.6     Extension of Services by Cord Blood Banks    17

2.    CORD BLOOD & CORD BLOOD BANKING: AN OVERVIEW    18

2.1    Cord Blood Banking (Stem Cell Banking)    18
2.1.1     Public Cord Blood Banks    19
2.1.1.1     Economic Model of Public Cord Blood Banks    19
2.1.1.2     Cost Analysis for Public Banks    21
2.1.1.3     Relationship between Costs and Release Rates    22
2.1.2    Private Cord Blood Banks    22
2.1.2.1     Cost Analysis for Private Cord Blood Banks    23
2.1.2.2     Economic Model of Private Banks    23
2.1.3     Hybrid Cord Blood Banks    24
2.2    Globally Known Cord Blood Banks    25
2.2.1     Comparing Cord Blood Banks    26
2.2.2     Cord Blood Banks in the U.S.    27
2.2.3     Proportion of Public, Private and Hybrid Banks    29
2.3    Percent Share of Parents of Newborns Storing Cord Blood by Country/Region    29
2.4    Pricing for Processing and Storage in Commercial Banks    30
2.4.1     Rate per Cord Blood Unit in the U.S. and Europe    31
2.5    Cord Blood Revenues for Major Cord Blood Banks    32

3.    CORD BLOOD BANK ACCREDITATIONS    33

3.1    American Association of Blood Banks (AABB)    33
3.2    Foundation for the Accreditation of Cellular Therapy (FACT)    33
3.3    FDA Registration    33
3.4    FDA Biologics License Application (BLA) License    34
3.5    Investigational New Drug (IND) for Cord Blood    34
3.6    Human Tissue Authority (HTA)    34
3.7    Therapeutic Goods Act (TGA) in Australia    34
3.8    International NetCord Foundation    35
3.9    AABB Accredited Cord Blood Facilities    35
3.10    FACT Accreditation for Cord Blood Banks    38

4.    APPLICATIONS OF CORD BLOOD CELLS    39

4.1    Hematopoietic Stem Cell Transplantations with Cord Blood Cells    39
4.2    Cord Cells in Regenerative Medicine    41
5.    CORD BLOOD PROCESSING TECHNOLOGIES    43

5.1    The Process of Separation    43
5.1.1     PrepaCyte-CB    44
5.1.2    Advantages of PrepaCyte-CB    45
5.1.3     Treatment Outcomes with PrepaCyte-CB    45
5.1.4     Hetastarch (HES)    46
5.1.5     AutoXpress (AXP)    46
5.1.6     SEPAX    47
5.1.7     Plasma Depletion Method (MaxCell Process)    48
5.1.8     Density Gradient Method    48
5.2    Comparative Merits of Different Processing Methods    49
5.2.1     Early Stage HSC Recovery by Technologies    50
5.2.2     Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood    51
5.2.3     Late Stage Recovery of HSCs from Cord Blood    52
5.3    HSC (CD45+) Recovery    52
5.4    Days to Neutrophil Engraftment by Technology    53
5.5    Anticoagulants used in Cord Blood Processing    54
5.5.1     Type of Anticoagulant and Cell Recovery Volume    55
5.5.2     Percent Cell Recovery by Sample Size    56
5.5.3     TNC Viability by Time Taken for Transport and Type of Anticoagulant    57
5.6    Cryopreservation of Cord Blood Cells    58
5.7    Bioprocessing of Umbilical Cord Tissue (UCT)    60
5.8    A Proposal to Improve the Utilization Rate of Banked Cord Blood    61

6.    CORD BLOOD CLINICAL TRIALS, SCIENTIFIC PUBLICATIONS & NIH FUNDING    64

6.1    Cord Blood Cells for Research    64
6.2    Cord Blood Cells for Clinical Trials    65
6.2.1     Number of Clinical Trials involving Cord Blood Cells    66
6.2.2     Number of Clinical Trials using Cord Blood Cells by Geography    67
6.2.3     Number of Clinical Trials by Study Type    68
6.2.4     Number of Clinical Trials by Study Phase    69
6.2.5     Number of Clinical Trials by Funder Type    70
6.2.6     Clinical Trials Addressing Indications in Children    71
6.2.7     Select Three Clinical Trials Involving Children    72
6.2.7.1     Sensorineural Hearing Loss (NCT02038972)    73
6.2.7.2     Autism Spectrum (NCT02847182)    73
6.2.7.3     Cerebral Palsy (NCT01147653)    73
6.2.8     Clinical Trials for Neurological Diseases using Cord Blood and Cord Tissue    74
6.2.9     UCB for Diabetes    75
6.2.10     UCB in Cardiovascular Clinical Trials    76
6.2.11     Cord Blood Cells for Auto-Immune Diseases in Clinical Trials    76
6.2.12     Cord Tissue Cells for Orthopedic Disorders in Clinical Trials    77
6.2.13     Cord Blood Cells for Other Indications in Clinical Trials    78
6.3    Major Diseases Addressed by Cord Blood Cells in Clinical Trials    79
6.4    Clinical Trials using Cord Tissue-Derived MSCs    79
6.5    Ongoing Clinical Trials using Cord Tissue    81
6.5.1     Cord Tissue-Based Clinical Trials by Geography    81
6.5.2     Cord Tissue-Based Clinical Trials by Phase    82
6.5.3     Cord Tissue-Based Clinical Trials by Sponsor Types    83
6.5.4     Companies S-ponsoring in Trials using Cord Tissue-Derived MSCs    84
6.6    Wharton’s Jelly-Derived MSCs in Clinical Trials    85
6.6.1    Wharton’s Jelly-Based Clinical Trials by Phase    85
6.6.2    Companies Sponsoring Wharton’s Jelly-Based Clinical Trials    86
6.7    Clinical Trials Involving Cord Blood Expansion Studies    87
6.7.1     Safe and Feasible Expansion Protocols    87
6.7.2     List of Clinical Trials involved in the Expansion of Cord Blood HSCs    88
6.7.3     Expansion Technologies    93
6.8    Scientific Publications on Cord Blood    95
6.9    Scientific Publications on Cord Tissue    96
6.10    Scientific Publications on Wharton’s Jelly-Derived MSCs    97
6.11    Published Scientific Papers on Cord Blood Cell Expansion    98
6.12    NIH Funding for Cord Blood Research    99

7.    PARENT’S AWARENESS AND ATTITUDE TOWARDS CORD BLOOD BANKING    100

7.1    Undecided Expectant Parents    100
7.2    The Familiar Cord Blood Banks Known by the Expectant Parents    101
7.3    Factors Influencing the Choice of a Cord Blood Bank    102

8.    CORD BLOOD: AS A TRANSPLANTATION MEDICINE    103

8.1    Comparisons of Cord Blood to other Allograft Sources    104
8.1.1     Major Indications for HCTs in the U.S.    105
8.1.2     Trend in Allogeneic HCT in the U.S. by Recipient Age    106
8.1.3     Trends in Autologous HCT in the U.S. by Recipient Age    107
8.2    HCTs by Cell Source in Adult Patients    108
8.2.1     Transplants by Cell Source in Pediatric Patients    109
8.3    Allogeneic HCTs by Cell Source    110
8.3.1     Unrelated Donor Allogeneic HCTs in Patients <18 Years    111
8.4    Likelihood of Finding an Unrelated Cord Blood Unit by Ethnicity    112
8.4.1     Likelihood of Finding an Unrelated Cord Blood Unit for Patients <20 Years    113
8.5    Odds of using a Baby’s Cord Blood    114
8.6    Cord Blood Utilization Trends    115
8.7    Number of Cord Blood Donors Worldwide    116
8.7.1     Number of CBUs Stored Worldwide    117
8.7.2     Cord Blood Donors by Geography    118
8.7.2.1     Cord Blood Units Stored in Different Geographies    119
8.7.2.2     Number of Donors by HLA Typing    120
8.7.3     Searches Made by Transplant Patients for Donors/CBUs    121
8.7.4    Types of CBU Shipments (Single/Double/Multi)    122
8.7.5     TNC Count of CBUs Shipped for Children and Adult Patients    123
8.7.6     Shipment of Multiple CBUs    124
8.7.7     Percent Supply of CBUs for National and International Patients    125
8.7.8     Decreasing Number of CBU Utilization    126
8.8    Top Ten Countries in Cord Blood Donation    127
8.8.1     HLA Typed CBUs by Continent    128
8.8.2     Percentage TNC of Banked CBUs    129
8.8.3     Total Number of CBUs, HLA-Typed Units by Country    130
8.9    Cord Blood Export/Import by E.U. Member States    137
8.9.1     Number of Donors and CBUs in Europe    138
8.9.2     Number of Exports/Imports of CBUs in E.U.    139
8.10    Global Exchange of Cord Blood Units    140

9.    CORD BLOOD CELLS AS THERAPEUTIC CELL PRODUCTS IN CELL THERAPY    143

9.1    MSCs from Cord Blood and Cord Tissue    143
9.1.1     Potential Neurological Applications of Cord Blood-Derived Cells    144
9.1.2     Cord Tissue-Derived MSCs for Therapeutic use    146
9.1.2.1     Indications Targeted by UCT-MSCs in Clinical Trials    147
9.2    Current Consumption of Cord Blood Units by Clinical Trials    147
9.3    Select Cord Blood Stem Cell Treatments in Clinical Trials    149
9.3.1     Acquired Hearing Loss (NCT02038972)    149
9.3.2     Autism (NCT02847182)    150
9.3.3     Cerebral Palsy (NCT03087110)    150
9.3.4     Hypoplastic Left Heart Syndrome (NCT01856049)    150
9.3.5     Type 1 Diabetes (NCT00989547)    151
9.3.6     Psoriasis (NCT03765957)    151
9.3.7     Parkinson’s Disease (NCT03550183)    151
9.3.8     Signs of Aging (NCT04174898)    152
9.3.9     Stroke (NCT02433509)    152
9.3.10     Traumatic Brain Injury (NCT01451528)    152


10.    MARKET ANALYSIS    153

10.1    Public vs. Private Cord Blood Banking Market    155
10.2    Cord Blood Banking Market by Indication    156

11.    PROFILES OF SELECT CORD BLOOD BANKS    158

11.1    AllCells    158
11.1.1     Whole Blood    158
11.1.2     Leukopak    159
11.1.3     Mobilized Leukopak    159
11.1.4     Bone Marrow    159
11.1.5     Cord Blood    160
11.2    AlphaCord LLC    160
11.2.1     NextGen Collection System    160
11.3    Americord Registry, Inc.    161
11.3.1     Cord Blood 2.0    161
11.3.2     Cord Tissue    161
11.3.3     Placental Tissue 2.0    162
11.4    Be The Match    163
11.4.1     Hub of Transplant Network    164
11.4.2     Partners of Be The Match    165
11.4.3     Allogeneic Cell Sources in Be The Match Registry    166
11.4.4     Likelihood of a Matched Donor on Be The Match by Ethnic Background    167
11.5    Biocell Center Corporation    169
11.5.1     Chorionic villi after Delivery    169
11.5.2     Amniotic Fluid and Chorionic Villi during Pregnancy    169
11.6    BioEden Group, Inc.    170
11.6.1     Differences between Tooth Cells and Umbilical Cord Cells    170
11.7    Biovault Family    171
11.7.1     Personalized Cord Blood Processing    171
11.8    Cell Care    172
11.9    Cells4Life Group, LLP    173
11.9.1     Cells4Life’s pricing    173
11.9.2     TotiCyte Technology    174
11.9.3     Cord Blood Releases    174
11.10    Cell-Save    175
11.11    Center for International Blood and Marrow Transplant Research (CIBMTR)    176
11.11.1     Global Collaboration    176
11.11.2     Scientific Working Committees    176
11.11.3     Medicare Clinical Trials and Studies    177
11.11.4     Cellular Therapy    177
11.12    Crio-Cell International, Inc.    181
11.12.1     Advanced Collection Kit    181
11.12.2     Prepacyte-CB    181
11.12.3     Crio-Cell International’s Pricing    182
11.12.4     Revenue for Crio-Cell International    182
11.13    Cord Blood Center Group    184
11.13.1     Cord Blood Units Released    184
11.14    Cordlife Group, Ltd.    187
11.14.1     Cordlife’s Cord Blood Release Track Record    187
11.15    Core23 Biobank    190
11.16    Cord Blood Registry (CBR)    191
11.17    Cordlife Group, Ltd.    193
11.18    CordVida    194
11.19    Crioestaminal    195
11.19.1     Cord Blood Transplantation in Portugal    195
11.20    Cryo-Cell International, Inc.    196
11.20.1     Processing Method    196
11.20.2     Financial Results of the Company    196
11.21    CryoHoldco    197
11.22    Cryoviva Biotech Pvt. Ltd    197
11.23    European Society for Blood and Bone Marrow Transplantation (EBMT)    198
11.23.1     EBMT Transplant Activity    198
11.24    FamiCord Group    200
11.25    GeneCell International    200
11.26    Global Cord Blood Corporation    201
11.26.1     The Company’s Business    201
11.27    HealthBaby Hong Kong    202
11.27.1     BioArchive System Service Plan    203
11.27.2     MVE Liquid Nitrogen System    203
11.28    HEMAFUND    203
11.29    Insception Lifebank    204
11.30    LifebankUSA    205
11.30.1     Placental Banking    205
11.31    LifeCell International Pvt. Ltd.    206
11.32    MiracleCord, Inc.    207
11.33    Maze Cord Blood Laboratories    208
11.34    New England Cord Blood Bank, Inc.    209
11.35    New York Cord Blood Center (NYBC)    210
11.35.1     Products    210
11.35.2     Laboratory Services    210
11.36    PacifiCord    212
11.36.1     FDA-Approved Sterile Collection Bags    212
11.36.2     AXP Processing System    212
11.36.3     BioArchive System    212
11.37    ReeLabs Pvt. Ltd.    213
11.38    Smart Cells International, Ltd.    214
11.39    Stem Cell Cryobank    215
11.40    StemCyte, Inc.    216
11.40.1     StemCyte Sponsored Clinical Trials    216
11.40.1.1    Spinal Cord Injury Phase II    216
11.40.1.2    Other Trials    216
11.41    Transcell Biolife    217
11.41.1     ScellCare    217
11.41.2     ToothScell    217
11.42    ViaCord    218
11.43    Vita 34 AG    219
11.44    World Marrow Donor Association (WMDA)    220
11.44.1     Search & Match Service    220
11.45    Worldwide Network for Blood & Marrow Transplantation (WBMT)    221
 

INDEX OF FIGURES

FIGURE 2.1: Profit Margins of Select Private Cord Blood Banks, 2016-2019    25
FIGURE 2.2: Cord Blood Banks by Size of Inventory    28
FIGURE 2.3: Proportion of Public, Private and Hybrid Banks    30
FIGURE 2.4: Percent Share of Parents of Newborns Storing Cord Blood by Country/Region    31
FIGURE 2.5: Cord Blood Revenues for Companies, 2016-2019    33

FIGURE 3.1: Percent Share of AABB Accredited Cord Blood Facilities by Country    38

FIGURE 5.1: Separation of Buffy Layer    44
FIGURE 5.2: PrepaCyte-CB    45
FIGURE 5.3: Hetastarch (HES)    47
FIGURE 5.4: AutoXpress II    48
FIGURE 5.5: SEPAX 2    48
FIGURE 5.6: Plasma Depletion (PD) Method (MaxCell Process)    49
FIGURE 5.7: Density Gradient Separation of Cord Blood    50
FIGURE 5.8: Early Stage HSC Recovery from Cord Blood by Technologies    51
FIGURE 5.9: Mid Stage HSC (CD34+/CD133+) Recovery from Cord Blood by Technologies    52
FIGURE 5.10: Late Stage HSC Recovery from Cord Blood by Technologies    53
FIGURE 5.11: HSC (CD45+) Recovery Post Process from Whole Blood by Technologies    54
FIGURE 5.12: Days to Neutrophil Engraftment by Technology    55
FIGURE 5.13: Difference in TNC Recovery among Anticoagulants    56
FIGURE 5.14: Type of Anticoagulant and Cell Recovery Volume    57
FIGURE 5.15: Percent Cell Recovery by Sample Size    58
FIGURE 5.16: TNC Viability by Time Taken for Transport    59
FIGURE 5.17: Difference in Recovery of Viable TNC after Thawing    60
FIGURE 5.18: CD34+ Cell Count, CFU and Cell Apoptosis by Cryoprotectants    61
FIGURE 5.19: The Number of Stored and Transplanted CB Units in Korea-CORD by TNC    62
FIGURE 5.20: Number of Stored and Shipped CB Units and Utilization Rate by TNC Count    63

FIGURE 6.1: Number of Clinical Trials as Reported in PubMed.gov from 2000 to 2019    68
FIGURE 6.2: Number of Cord Blood Clinical Trials by Geography as of June 2020    69
FIGURE 6.3: Number of Cord Blood Clinical Trials by Study Type as of June 2020    70
FIGURE 6.4: Number of Cord Blood Clinical Trials by Study Phase as of June 2020    71
FIGURE 6.5: Number of Cord Blood Clinical Trials by Funder Type as of June 2020    72
FIGURE 6.6: Percent Share of Indications in Children tested in Clinical Trials    73
FIGURE 6.7: Percent Share of Diseases in Ongoing Clinical Trials using Cord Blood Cells    80
FIGURE 6.8: Percent Share of Diseases in Clinical Trials using MSCs from Cord Tissue    81
FIGURE 6.9: Number of Cord Tissue-Based Clinical Trials by Geography as of June 2020    83
FIGURE 6.10: Cord Tissue-Based Clinical Trials by Study Phase as of June 2020    84
FIGURE 6.11: Cord Tissue-Based Clinical Trials by Funder Type as of June 2020    85
FIGURE 6.12: Wharton’s Jelly-Based Clinical Trials by Study Phase as of June 2020    87
FIGURE 6.13: Number of Published Scientific Papers on UCB, 2000-June 2020    96
FIGURE 6.14: Number of Published Scientific Papers on Cord Tissue, 2000-June 2020    97
FIGURE 6.15: Number of Published Scientific Papers on Wharton’s Jelly, 2000-June 2020    98
FIGURE 6.16: Number of Published Scientific Papers on Cord Blood Expansion    99

FIGURE 7.1: Percent Expectant Parents who have heard about Cord Blood Banking    101
FIGURE 7.2: Undecided Expectant Parents about Cord Blood Banking    102
FIGURE 7.3: The Familiar Cord Blood Banks Known by the Expectant Parents    102
FIGURE7.4: Factors Influencing the Choice of a Cord Blood Bank    103

FIGURE 8.1: Distribution of Cell Sources in HCTs as Reported in Be The Match, 2019    104
FIGURE 8.2: Comparisons of Cord Blood to other Allograft Sources    105
FIGURE 8.3: Major Indications for HTC in the U.S., 2019    107
FIGURE 8.4: Trend in Allogeneic HCT in the U.S. by Recipient Age, 2000-2018    108
FIGURE 8.5: Trends in Autologous HCT in the U.S. by Recipient Age, 2000-2018    109
FIGURE 8.6: Transplants by Cell Source in Adult Patients, 2010-2019    110
FIGURE 8.7: Transplants by Cell Source in Pediatric Patients <18 Years    111
FIGURE 8.8: Allogeneic HCTs by Cell Source Facilitated by NMDP/Be The Match    112
FIGURE 8.9: Unrelated Donor Allogeneic HCTs in Patients <18 Years/NMDP/Be The Match    113
FIGURE 8.10: Likelihood of Finding an Unrelated Cord Blood Unit by Ethnicity    114
FIGURE 8.11: Likelihood of Finding an Unrelated Cord Blood Unit for Patients <20 Years    115
FIGURE 8.12: Cumulative Probability of having a Stem Cell Transplant by Age    116
FIGURE 8.13: Cord Blood Utilization Trends    117
FIGURE 8.14: Number of UCB Donors Worldwide as Reported by WMDA    118
FIGURE 8.15: Number of CBUs Worldwide as Reported by WMDA    119
FIGURE 8.16: Number of Umbilical Cord Blood Donors by Geography    120
FIGURE 8.17: Number of Cord Blood Units Stored by Geography    121
FIGURE 8.18: Percent Shares of all Registered Donors by HLA Typing Level    122
FIGURE 8.19: Number of Searches Initiated by National Patients for Donors/CBU/Both    123
FIGURE 8.20: Types of CBU Shipments    124
FIGURE 8.21: TNC Count of CBUs Provided for Children and Adult Patients - Single    125
FIGURE 8.22: TNC Count of CBUs Provided for Children and Adult Patients - Multi    126
FIGURE 8.23: Percentage of HPC Products Provided for National and International Patients    127
FIGURE 8.25: Top Ten Countries with Number of Donors Listed per 10,000 Inhabitants    129
FIGURE 8.26: Percentage of HLA Typed CBUs Banked per Continent    130
FIGURE 8.27: Percentage TNC of Banked CBUs    131
FIGURE 8.28: Number of Donors per 10,000 Inhabitants by Select E.U. Countries    139
FIGURE 8.29: Global CBU Shipments by Geography in 2018    142
FIGURE 8.30: Global Shipments of CBUs by Geography in 2012    143

FIGURE 9.1: Percent Shares of Indications Targeted by UCB-MSCs in Clinical Trials    146
FIGURE 9.2: Percent Share of Clinical Indications using UCT-MSCs    148
FIGURE 9.3: Number of UCB Units Released by Cord Blood Registry by Application    150

FIGURE 10.1: Global Cord Blood Banking Market Revenue by Geography    155
FIGURE 10.2: Percent Share of Global Cord Blood Banking Market Revenue by Geography    156
FIGURE 10.3: Percent Share of Global Cord Blood Banking Market, Public vs. Private    157
FIGURE 10.4: Percent Share of Cord Blood Banking Market by Indication    158

FIGURE 11.1: Growth of CBUs on the Be The Match Registry    164
FIGURE 11.2: Growth of CBUs on the Be The Match Registry    165
FIGURE 11.3: Number of Unrelated Donor Transplants Facilitated by NMDP/Be The Match    166
FIGURE 11.4: Diversity of CBUs in Be The Match Registry    167
FIGURE 11.5: Cell Sources for Allogeneic HCT Facilitated by Be The Match Registry    168
FIGURE 11.6: Likelihood of a Matched Donor on Be The Match Registry by Ethnicity    169
FIGURE 11.7: Percent Recovery of Viable Cells by TotiCyte Technology    175
FIGURE 11.8: Growth in Number of New Transplant Patients Registered with the CIBMTR    178
FIGURE 11.9: New Patients per Year Registered with CIBMTR    179
FIGURE 11.10: Transplant Patients by Graft Source Registered with CIBMTR    180
FIGURE 11.11: Crio-Cell International’s Revenues, 2016-2019    184
FIGURE 11.12: Number of Cord Blood Units Stored in CBR and its Competitors    193
FIGURE 11.13: Key Figures of Sales Revenues and Gross Profits for Cordlife, 2014-2019    194
FIGURE 11.14: Revenue and Gross Profit for GCBC, 2015-2019    203
FIGURE 11.15: Percent Share of Units Released by Indication    215
FIGURE 11.16: Key Figures of Sales Revenues and Gross Profits for Vita 34, 2014-2019    220


INDEX OF TABLES

TABLE 2.1: An Overview of Public Cord Blood Banks    19
TABLE 2.2: International Prices of Cord Blood Unit    20
TABLE 2.3: Prices of Cord Blood Units in NMDP Banks in the U.S.    21
TABLE 2.4: An Overview of Private Cord Blood Banks    23
TABLE 2.5: Profit Margins of Select Private Cord Blood Banks, 2016-2019    24
TABLE 2.6: An Overview of Hybrid Cord Blood Banks    25
TABLE 2.7: A Partial List of Global Private Cord Blood Banks    26
TABLE 2.8: Comparison of Three Private Banks    27
TABLE 2.9: Partial List of Public, Private and Hybrid Cord Blood Banks in the U.S.    28
TABLE 2.10: Pricing for Storage in Commercial Banks    30
TABLE 2.11: Rate per Cord Blood Unit in the U.S. & Europe    31
TABLE 2.12: Cord Blood Revenues for Major Four Companies, 2016-2019    32

TABLE 3.1: AABB Accredited Cord Blood Facilities    35
TABLE 3.1: (CONTINUED)    36
TABLE 3.1: (CONTINUED)    37
TABLE 3.2: Select FACT Accredited Cord Blood Facilities    38

TABLE 4.1: Indications for the Use of UCB-Derived Stem Cells for Transplantation    39
TABLE 4.1: (CONTINUED)    40
TABLE 4.1: (CONTINUED)    41
TABLE 4.2: Indications for the Use of UCB-Derived Stem Cells for Regenerative Medicine    42

TABLE 5.1: Advantages of PrepaCyte-CB    45
TABLE 5.2: Treatment Outcomes with PrepaCyte-CB    45

TABLE 6.1: U.S. Cord Blood Banks Supplying Cord Blood for Research    65
TABLE 6.2: Number of Cord Blood Clinical Trials by Geography as of June 2020    68
TABLE 6.3: Number of Cord Blood Clinical Trials by Study Type as of June 2020    69
TABLE 6.4: Number of Cord Blood Clinical Trials by Study Phase as of June 2020    70
TABLE 6.5: Number of Cord Blood Clinical Trials by Funder Type as of June 2020    71
TABLE 6.6: Percent Share of Indications in Children tested in Clinical Trials    72
TABLE 6.7: Select Three Clinical Trials involving Children    74
TABLE 6.8: Ongoing Clinical Trials using UCB for Neurological Diseases    75
TABLE 6.9: Ongoing Clinical Trials using UCB for Diabetes    75
TABLE 6.10: Ongoing Clinical Trials using UCB for Cardiovascular Trials    76
TABLE 6.11: Ongoing Clinical Trials using UCB for Auto-Immune Diseases    77
TABLE 6.12: Ongoing Clinical Trials using UCB for Orthopedic Disorders    77
TABLE 6.13: Ongoing Clinical Trials using UCB for Other Indications    78
TABLE 6.14: Select Clinical Trials using MSCs from Cord Tissue    80
TABLE 6.15: Number of Cord Tissue-Based Clinical Trials by Geography as of June 2020    81
TABLE 6.16: Number of Cord Tissue-Based Clinical Trials by Study Phase as of June 2020    82
TABLE 6.17: Number of Cord Tissue-Based Clinical Trials by Funder Type as of June 2020    83
TABLE 6.18: Select Cord Tissue-Based Clinical Trials by Commercial Entities, 2020    84
TABLE 6.19: Wharton’s Jelly-Based Clinical Trials by Phase, 2020    85
TABLE 6.20: Wharton’s Jelly-Based Clinical Trials by Commercial Entities, June 2020    86
TABLE 6.21: Clinical Trials in Cord Blood-Derived Cell Expansion by Country, 2020    87
TABLE 6.22: Clinical Trials of Cell Expansion Studies by Stages in Development, 2020    88
TABLE 6.23: List of Clinical Trials involved in the Expansion of Cord Blood HSCs    88
TABLE 6.23: (CONTINUED)    89
TABLE 6.23: (CONTINUED)    90
TABLE 6.23: (CONTINUED)    91
TABLE 6.23: (CONTINUED)    93
TABLE 6.24: Cord Blood Expansion Approaches    94
TABLE 6.25: Select NIH Funding for Umbilical Cord Blood Research, 2019-2020    99

TABLE 8.1: Comparisons of Cord Blood to other Allograft Sources in Transplantation    104
TABLE 8.2: Number of HCTs Performed in the U.S. as reported to CIBMTR by Disease    105
TABLE 8.3: Total Number of Cord Blood Donors and Cord Blood Units by Country    131
TABLE 8.3: (CONTINUED)    132
TABLE 8.3: (CONTINUED)    135
TABLE 8.3: (CONTINUED)    136
TABLE 8.3: (CONTINUED)    137
TABLE 8.4: Number of Donors and CBUs by E.U. Country as of December 31, 2018    139
TABLE 8.5: Number of Exports/Imports of CBUs in E.U. in 2018    140

TABLE 9.1: Select 15 Clinical Trials Using Cord Blood-Derived MSCs as Interventions    144
TABLE 9.2: Select Clinical Trials using UCT-MSCs as Interventions    146

TABLE 10.1: Global Cord Blood Banking Market Revenue by Geography    154

TABLE 11.1: AlphaCord’s pricing    160
TABLE 11.2: Cell Care’s pricing for Processing and Storage    172
TABLE 11.3: Cells4Life’s pricing for Cord Blood, Cord Tissue, Amnion and Placental Cells    173
TABLE 11.4: Cord Blood and Cord Tissue Products Released from Cells4Life    175
TABLE 11.5: Distribution of Transplant Patients by Graft Source Registered with CIBMTR    179
TABLE 11.6: Distribution of Transplant Patients by Indication Registered with CIBMTR    180
TABLE 11.7: Crio-Cell International’s pricing for Processing and Storage    182
TABLE 11.8: Crio-Cell International’s Revenues, 2016-2019    182
TABLE 11.9: Cord Blood Units Released from Cord Blood Center Group    184
TABLE 11.9: (CONTINUED)    185
TABLE 11.9: (CONTINUED)    186
TABLE 11.10: Cordlife’s Cord Blood Release Track Record    187
TABLE 11.10: (CONTINUED)    188
TABLE 11.10: (CONTINUED)    189
TABLE 11.11: Core23 Biobank’s Processing and Storage Fees    190
TABLE 11.12: Allogeneic and Autologous Transplantations by Indication Reported in EBMT    199
TABLE 11.13: GeneCell Internationals Prepaid Storage Plans    200
TABLE 11.14: Selected Financial Data for GCBC, 2015-2019    201
TABLE 11.15: Insception Lifebank’s Pricing    204
TABLE 11.16: LifeCell International’s pricing    206
TABLE 11.17: MiracleCord’s Cost Comparison with Competitors    207
TABLE 11.18: Maze Cord Blood Laboratory’s Payment Plans    208
TABLE 11.19: Comparison of Pricing of NECBB with others    209
TABLE 11.20 Stem Cell Cryobank’s pricing for Processing and Storage    215